Search
Apomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigationalApomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an e...
Quercus alba pollen
go.drugbank.com/drugs/DB10376ApprovedQuercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen. It can be subcutaneously administered to initiate an immune response in case of an...
Mixtures: 5-oak Mix, Blackjack/bur/post/red/white PollenInfluenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14587ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Mixtures: FLUZONE High-DoseChymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487] … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.
Metamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawnMetamizole (dipyrone) is a pyrazolone derivative that belongs to the group of nonacid nonopioids. It is considered a potent analgesic and antipyretic with favourable gastrointestinal tolerability. Metamizole was formerly marketed in the ...
Phenformin
go.drugbank.com/drugs/DB00914ApprovedWithdrawnAlthough it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries.
Afatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationaloral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by
Pramipexole
go.drugbank.com/drugs/DB00413ApprovedInvestigationalParkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients [A176855], leading to increased difficulty in performing activities of daily … It was first approved by the FDA in 1997 [L5882].
Amsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnIt produces consistent but acceptable myelosuppression and cardiotoxic effects. … It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors.
Midostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potent...